Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis
Ciclosporin (Atopica; Novartis Animal Health) has been licensed for canine atopic dermatitis (AD) since 2002. Adverse events (AEs) have been reported in 55 per cent of 759 dogs in 15 clinical trials, but are rare in pharmacovigilance data (71.81 AEs/million capsules sold). Gastrointestinal reactions...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BMJ Group
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995266/ |